H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $29 from $30 and keeps a Buy rating on the shares following the Q4 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions
- Oculis Holding AG Reports 2024 Financial Results
- Oculis Holding’s Promising Ophthalmology Portfolio and Financial Stability Lead to Buy Rating
- Oculis Holding AG Reports 2024 Financial Results and Clinical Progress
- Oculis 5M share Secondary priced at $20,00